(RTTNews) - Merck & Co., Inc. (MRK) announced positive results from the Phase 3 KEYNOTE-C93 trial, evaluating KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, as monotherapy for the treatment of patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.